SCHEMBL7776281

SCHEMBL7776281

NC(=O)[C@@H](N)CCC(=O)c1ccc(O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
BLM P54132 2/20 0.53
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
ABL1 P00519 1/20 0.53
POLB P06746 1/20 0.53
ALPI P09923 1/20 0.53
GAA P10253 1/20 0.53
ALPG P10696 1/20 0.53
APEX1 P27695 1/20 0.53
CASP3 P42574 1/20 0.53
RECQL P46063 1/20 0.53
CASP7 P55210 1/20 0.53
CASP6 P55212 1/20 0.53
MCL1 Q07820 1/20 0.53
RIN1 Q13671 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HSD17B3 P37058 8/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29098319 0.86 NPC1 (0.55) NPC1RAB9ABLMKDM4EALDH1A1
SCHEMBL8935094 0.81 CA12 (0.43) KDM4EPOLBALPIGAAALPG
SCHEMBL22546667 0.80 HSD17B3 (0.58) NPC1RAB9ABLMKDM4EALDH1A1
SCHEMBL2912668 0.78 ESR1 (0.40) BLMKDM4EALDH1A1POLBRECQL
SCHEMBL7939950 0.76 NPC1 (0.81) NPC1RAB9ABLMKDM4EALDH1A1
SCHEMBL10474694 0.76 HSD17B3 (0.62) NPC1RAB9ABLMKDM4EALDH1A1
SCHEMBL4658680 0.75 BLM (0.47) NPC1RAB9ABLMKDM4EALDH1A1
SCHEMBL4658683 0.75 BLM (0.47) NPC1RAB9ABLMKDM4EALDH1A1
SCHEMBL23700720 0.74 SLC7A5 (0.52) BLMKDM4EALDH1A1TDP1L3MBTL1
SCHEMBL28133919 0.73 NPC1 (0.58) NPC1RAB9ABLMKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3380120-B1 IMMUNOSTIMULATORY COMPOSITIONS HOPITAUX PARIS ASSIST PUBLIQUE (FR) 2021-04-21 EP disclosed
US-20210060156-A1 IMMUNOSTIMULATORY COMPOSITIONS ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) 2021-03-04 US disclosed
EP-3173098-A1 IMMUNOSTIMULATORY COMPOSITIONS ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (FR) 2017-05-31 EP disclosed
EP-0547065-B1 MELANIN PRODUCTION BY TRANSFORMED MICROORGANISMS LARGE SCALE BIOLOGY CORP (US) 2001-08-29 EP disclosed
US-5837505-A TRANSFORMATION OF MICROORGANISMS WITH VECTORS FORMING DNA SEQUENCES BIOSOURCE TECHNOLOGIES, INC. (US) 1998-11-17 US disclosed
US-5814495-A GROWING IN A CASEIN, COPPER SULFATE, DISSOLVED OXYGEN AND TYROSINE MEDIUM BIOSOURCE TECHNOLOGIES, INC. (US) 1998-09-29 US disclosed
US-5631151-A STREPTOMYCES BIOSOURCE TECHNOLOGIES, INC. (US) 1997-05-20 US disclosed
EP-0363792-B1 Melanin production BIOSOURCE GENETICS CORP (US) 1995-01-18 EP disclosed
EP-0363792-A1 Melanin production BIOSOURCE GENETICS CORPORATION (US) 1990-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210060156-A1 IMMUNOSTIMULATORY COMPOSITIONS CD47, CD74, LY96 NPC1 2691/4885RAB9A 1536/4885BLM 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.